Home › Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based...
 

Keywords :   


Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based...

2013-11-02 15:57:50| Biotech - Topix.net

Gilead Sciences, Inc. today announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus infection among patients co-infected with HIV.

Tags: results phase announces gilead

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11PM responds to Sir Alan Bates after repeated requests
05.11American Angus elects 2024-25 board leaders
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 8A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Brazil gives green light to medicinal use of Cannabis in animals
More »